Metastatic Prostate Cancer - Pipeline Review, H2 2014

Published: Oct, 2014 | Pages: 89 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Metastatic Prostate Cancer - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Metastatic Prostate Cancer - Pipeline Review, H2 2014', provides an overview of the Metastatic Prostate Cancer's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Metastatic Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Prostate Cancer and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Metastatic Prostate Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Metastatic Prostate Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Metastatic Prostate Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Metastatic Prostate Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Metastatic Prostate Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Metastatic Prostate Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Metastatic Prostate Cancer Overview 8
Therapeutics Development 9
Pipeline Products for Metastatic Prostate Cancer - Overview 9
Pipeline Products for Metastatic Prostate Cancer - Comparative Analysis 10
Metastatic Prostate Cancer - Therapeutics under Development by Companies 11
Metastatic Prostate Cancer - Therapeutics under Investigation by Universities/Institutes 13
Metastatic Prostate Cancer - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Metastatic Prostate Cancer - Products under Development by Companies 17
Metastatic Prostate Cancer - Products under Investigation by Universities/Institutes 18
Metastatic Prostate Cancer - Companies Involved in Therapeutics Development 19
AbbVie Inc. 19
Actinium Pharmaceuticals, Inc. 20
Camurus AB 21
Colby Pharmaceutical Company 22
Eli Lilly and Company 23
Fountain Biopharma Inc. 24
Johnson & Johnson 25
MedImmune, LLC 26
MEI Pharma, Inc. 27
OncoMax 28
OXiGENE, Inc. 29
Progenics Pharmaceuticals, Inc. 30
ValiRx Plc 31
Metastatic Prostate Cancer - Therapeutics Assessment 32
Assessment by Monotherapy Products 32
Assessment by Target 33
Assessment by Mechanism of Action 35
Assessment by Route of Administration 37
Assessment by Molecule Type 39
Drug Profiles 41
abiraterone acetate - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Actimab-P - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
CADD-522 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Cell Therapy to Target PSMA for Metastatic Prostate Cancer - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
CPC-410 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
FB-704A - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
KGP-94 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
leuprolide acetate - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
LU-901 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
LY-2495655 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
MEDI-6469 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
MIP-1095 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
MVI-118 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
OMRCA-01 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
pracinostat - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Recombinant Protein for Oncology - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Small Molecules for Oncology - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
VAC-1 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Vaccine For Oncolytic Newcastle Disease Virus - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
VAL-201 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
veliparib - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
Metastatic Prostate Cancer - Recent Pipeline Updates 69
Metastatic Prostate Cancer - Dormant Projects 80
Metastatic Prostate Cancer - Discontinued Products 81
Metastatic Prostate Cancer - Product Development Milestones 82
Featured News & Press Releases 82
Mar 27, 2014: OXiGENE Announces Presentation of Preclinical Abstracts at 2014 AACR Conference 82
Feb 06, 2014: ZYTIGA Now Reimbursed in Qu�bec for Use Prior to Chemotherapy in Men with Metastatic Prostate Cancer 82
Nov 21, 2013: ZYTIGA Now Available for Men with Metastatic Prostate Cancer in British Columbia Prior to Chemotherapy 83
May 29, 2013: Janssen's Zytiga Receives New Indication Approval From Health Canada For Treatment Of Metastatic Prostate Cancer 83
Jun 02, 2012: Zytiga's Phase III Results Show Significant Improvement In Radiographic Progression-Free Survival And Trend For Increased Overall Survival In Metastatic Prostate Cancer Patients 85
May 16, 2012: J&J's ZYTIGA Now Available For Eligible Patients In Nova Scotia, Newfoundland And Labrador For Prostate Cancer 86
Mar 04, 2005: Geron Announces Publication Of Phase 1-2 Telomerase Vaccine Study Results In Patients With Metastatic Prostate Cancer 86
Appendix 88
Methodology 88
Coverage 88
Secondary Research 88
Primary Research 88
Expert Panel Validation 88
Contact Us 89
Disclaimer 89

List of Tables
Number of Products under Development for Metastatic Prostate Cancer, H2 2014 9
Number of Products under Development for Metastatic Prostate Cancer - Comparative Analysis, H2 2014 10
Number of Products under Development by Companies, H2 2014 12
Number of Products under Investigation by Universities/Institutes, H2 2014 13
Comparative Analysis by Late Stage Development, H2 2014 14
Comparative Analysis by Clinical Stage Development, H2 2014 15
Comparative Analysis by Early Stage Development, H2 2014 16
Products under Development by Companies, H2 2014 17
Products under Investigation by Universities/Institutes, H2 2014 18
Metastatic Prostate Cancer - Pipeline by AbbVie Inc., H2 2014 19
Metastatic Prostate Cancer - Pipeline by Actinium Pharmaceuticals, Inc., H2 2014 20
Metastatic Prostate Cancer - Pipeline by Camurus AB, H2 2014 21
Metastatic Prostate Cancer - Pipeline by Colby Pharmaceutical Company, H2 2014 22
Metastatic Prostate Cancer - Pipeline by Eli Lilly and Company, H2 2014 23
Metastatic Prostate Cancer - Pipeline by Fountain Biopharma Inc., H2 2014 24
Metastatic Prostate Cancer - Pipeline by Johnson & Johnson, H2 2014 25
Metastatic Prostate Cancer - Pipeline by MedImmune, LLC, H2 2014 26
Metastatic Prostate Cancer - Pipeline by MEI Pharma, Inc., H2 2014 27
Metastatic Prostate Cancer - Pipeline by OncoMax, H2 2014 28
Metastatic Prostate Cancer - Pipeline by OXiGENE, Inc., H2 2014 29
Metastatic Prostate Cancer - Pipeline by Progenics Pharmaceuticals, Inc., H2 2014 30
Metastatic Prostate Cancer - Pipeline by ValiRx Plc, H2 2014 31
Assessment by Monotherapy Products, H2 2014 32
Number of Products by Stage and Target, H2 2014 34
Number of Products by Stage and Mechanism of Action, H2 2014 36
Number of Products by Stage and Route of Administration, H2 2014 38
Number of Products by Stage and Molecule Type, H2 2014 40
Metastatic Prostate Cancer Therapeutics - Recent Pipeline Updates, H2 2014 69
Metastatic Prostate Cancer - Dormant Projects, H2 2014 80
Metastatic Prostate Cancer - Discontinued Products, H2 2014 81